MAPKAPK5-AS1: A Potential Drug Target for Psychiatric Disorders

Target Name: MAPKAPK5-AS1

NCBI ID: G51275

MAPKAPK5-AS1

Other Name(s): C12orf47 | MAPKAPK5-AS1 variant 1 | MAAS | MAPKAPK5 antisense RNA 1 | MAPKAPK5 antisense RNA 1, transcript variant 1

MAPKAPK5-AS1: A Potential Drug Target for Psychiatric Disorders

MAPKAPK5-AS1 (C12orf47), a protein located in the brain, has been identified as a potential drug target or biomarker for various psychiatric and neurological disorders. The MAPKAPK5-AS1 gene, which encodes a protein involved in the cAMP-dependent translocation of the protein kinase APRF4, has been shown to be aberrantly expressed in individuals with schizophrenia, depression, and other psychiatric disorders.

The MAPKAPK5-AS1 protein is a key regulator of various cellular processes, including cell signaling, neurotransmission, and inflammation. It is a part of the MAPKAPK5 family, which is known to play a role in the regulation of MAPK (mechanistic adaption protein) signaling pathways. The MAPK signaling pathway is involved in the regulation of various cellular processes, including cell growth, differentiation, and survival.

MAPKAPK5-AS1 has been shown to be involved in the regulation of MAPK signaling in the brain. It has been shown to interact with the MAPK4 protein, which is a key regulator of MAPK signaling. The interaction between MAPKAPK5-AS1 and MAPK4 has been shown to play a role in the regulation of various cellular processes, including neuronal excitability and synaptic plasticity.

In addition to its role in MAPK signaling, MAPKAPK5-AS1 has also been shown to be involved in the regulation of other signaling pathways, including TGF-β and NF-kappa-B signaling pathways. These signaling pathways are involved in the regulation of various cellular processes , including cell growth, differentiation, and survival.

The aberrant expression of MAPKAPK5-AS1 in individuals with psychiatric and neurological disorders has been implicated in the development and progression of these disorders. For example, studies have shown that individuals with schizophrenia have lower levels of MAPKAPK5-AS1 compared to healthy individuals. Additionally, Individuals with depression have higher levels of MAPKAPK5-AS1 compared to healthy individuals.

In addition to its potential role as a drug target or biomarker, MAPKAPK5-AS1 is also of interest as a potential therapeutic approach for the treatment of psychiatric and neurological disorders. For example, inhibition of MAPKAPK5-AS1 has been shown to be effective in treating symptoms of schizophrenia, including positive symptoms such as hallucinations and delusions. Additionally, inhibition of MAPKAPK5-AS1 has been shown to be effective in treating symptoms of depression, including reduced symptoms of anxiety and insomnia.

In conclusion, MAPKAPK5-AS1 is a protein that has been shown to be involved in the regulation of various cellular processes, including cell signaling, neurotransmission, and inflammation. Its abnormal expression has been implicated in the development and progression of psychiatric and neurological disorders. In addition to its potential role as a drug target or biomarker, MAPKAPK5-AS1 is also of interest as a potential therapeutic approach for the treatment of psychiatric and neurological disorders. Further research is needed to fully understand the role of MAPKAPK5-AS1 in the regulation of cellular processes and its potential as a therapeutic approach for the treatment of psychiatric and neurological disorders.

Protein Name: MAPKAPK5 Antisense RNA 1

The "MAPKAPK5-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MAPKAPK5-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets